Vedolizumab combined with surgical resection successfully treated perforating Crohn's disease with peritoneal space to rectal and vaginal fistulas: a case report

BMC Gastroenterol. 2021 Jul 29;21(1):299. doi: 10.1186/s12876-021-01875-6.

Abstract

Background: Intestinal perforations and fistulas are common complications of Crohn's disease. However, chronic perforation with peritoneal space to rectal and vaginal fistulas have not been previously reported.

Case presentation: A 38-year-old female suffered from progressive lower abdominal pain, diarrhea and weight loss. Terminal ileal chronic perforation with intra-abdominal abscess, peritoneal space to rectal and vaginal fistulas were noted. The patient received surgical resection of the cecum and terminal ileum, and then vedolizumab treatment. Three months later, she had complete fistula closure, and her body mass index had increased from 13 to 22.

Conclusion: Vedolizumab combined with stool diversion is effective at treating Crohn's disease with chronic perforation and complex peritoneal space to rectal and vaginal fistulas.

Keywords: Crohn’s disease; Fistula; Perforation; Surgery; Vedolizumab.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Crohn Disease* / complications
  • Crohn Disease* / drug therapy
  • Crohn Disease* / surgery
  • Female
  • Humans
  • Intestinal Fistula*
  • Treatment Outcome
  • Vaginal Fistula*

Substances

  • Antibodies, Monoclonal, Humanized
  • vedolizumab